Evidence map›Paper›PMID 38572926›Full record

ArticleCancer medicine2024

Treatment outcome and germline predictive factors of ropeginterferon alpha-2b in myeloproliferative neoplasm patients.

Chih-Cheng Chen, Ming-Chung Kuo, Ying-Hsuan Wang, Sung-Nan Pei, Ming-Lih Huang, Chiu-Chen Chen, Cih-En Huang, Yi-Yang Chen, Lee-Yung Shih

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Chih-Cheng ChenDivision of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Ming-Chung KuoCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Ying-Hsuan WangDivision of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Sung-Nan PeiDepartment of Hema-Oncology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
Ming-Lih HuangDivision of Hematology and Oncology, Da Chien General Hospital, Miaoli, Taiwan.
Chiu-Chen ChenDivision of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
Cih-En HuangDivision of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Yi-Yang ChenDivision of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Lee-Yung ShihCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0003-1866-7922
Chang Gung University · TWChiayi Chang Gung Memorial Hospital · TWI-Shou University · TWYu Da University · TW

Funding

Chang Gung Memorial Hospital, Linkou DOH-102-TD-C-111-006Chang Gung Memorial Hospital, Linkou NSTC112-2314-B-182-055Chang Gung Memorial Hospital, Linkou XPRPG3H0011-16Chiayi Chang Gung Memorial Hospital COPRG6K0023Chiayi Chang Gung Memorial Hospital CORPG6K0013
6 · The paper itself

Abstract

backgroundStudies have shown that some single nucleotide polymorphisms (SNPs) could serve as excellent markers in foretelling the treatment outcome of interferon (IFN) in myeloproliferative neoplasms (MPN). However, most work originated from western countries, and data from different ethnic populations have been lacking.

methodsTo gain insights, targeted sequencing was performed to detect myeloid-associated mutations and SNPs in eight loci across three genes (IFNL4, IFN-γ, and inosine triphosphate pyrophosphatase [ITPA]) to explore their predictive roles in our cohort of 21 ropeginterferon alpha-2b (ROPEG)-treated MPN patients, among whom real-time quantitative PCR was also performed periodically to monitor the JAK2V617F allele burden in 19 JAK2V617F-mutated cases.

resultsELN response criteria were adopted to designate patients as good responders if they achieved complete hematological responses (CHR) within 1 year (CHR1) or attained major molecular responses (MMR), which occurred in 70% and 45% of the patients, respectively. IFNL4 and IFN-γ gene SNPs were infrequent in our population and were thus excluded from further analysis. Two ITPA SNPs rs6051702 A>C and rs1127354 C>A were associated with an inferior CHR1 rate and MMR rate, respectively. The former seemed to be linked to grade 2 or worse hepatotoxicity as well, although the comparison was of borderline significance only (50%, vs. 6.7% in those with common haplotype, p = 0.053). Twelve patients harbored 19 additional somatic mutations in 12 genes, but the trajectory of these mutations varied considerably and was not predictive of any response.

conclusionsOverall, this study provided valuable information on the ethnics- and genetics-based algorithm in the treatment of MPN.

Indexed as

Myeloproliferative DisordersNeoplasmsGerm CellsHaplotypesHumansInterferon LambdaInterleukinsTreatment OutcomeIFNL4 protein, humanInterferon LambdaInterleukinsAsianhematological responsesmolecular responsesmyeloproliferative neoplasmpolycythemia veraropeginterferon alpha‐2bsingle nucleotide polymorphisms

Identifiers

PMID38572926
PMCPMC10993704
OpenAlexW4393949424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.